JP2007509607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509607A5 JP2007509607A5 JP2006530599A JP2006530599A JP2007509607A5 JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5 JP 2006530599 A JP2006530599 A JP 2006530599A JP 2006530599 A JP2006530599 A JP 2006530599A JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- acid construct
- antigen
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50993603P | 2003-10-10 | 2003-10-10 | |
| US60/509,936 | 2003-10-10 | ||
| PCT/GB2004/004279 WO2005035771A2 (en) | 2003-10-10 | 2004-10-11 | Nucleic acid constructs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509607A JP2007509607A (ja) | 2007-04-19 |
| JP2007509607A5 true JP2007509607A5 (cg-RX-API-DMAC7.html) | 2007-12-06 |
| JP4814099B2 JP4814099B2 (ja) | 2011-11-09 |
Family
ID=34435038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530599A Expired - Fee Related JP4814099B2 (ja) | 2003-10-10 | 2004-10-11 | 核酸構築物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8663657B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1685251B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4814099B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101234981B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1890375B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004279991B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0415204A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2542288A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1685251T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA010056B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2457022T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL174848A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06003978A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20062080L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ546554A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1685251T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1685251E (cg-RX-API-DMAC7.html) |
| SG (1) | SG147430A1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI1685251T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005035771A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200603685B (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
| CN101365494A (zh) * | 2005-10-05 | 2009-02-11 | 贝希尔治疗学股份有限公司 | 治疗自身免疫性疾病的组合物和方法 |
| NZ589268A (en) | 2008-07-23 | 2012-06-29 | Boehringer Ingelheim Pharma | Novel regulatory elements (polyadenylation signals and vectors comprising the signal) to improve gene expression |
| EP3318248B1 (en) * | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| CN101993878B (zh) * | 2010-10-14 | 2012-04-18 | 南京农业大学 | 一种rRNA嵌合启动子及含有该嵌合启动子的表达载体 |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| RU2750261C2 (ru) * | 2012-03-27 | 2021-06-25 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков и пептидов |
| RU2660565C2 (ru) * | 2012-03-27 | 2018-07-06 | Кьюрвак Аг | Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top |
| EP2831239B1 (en) * | 2012-03-27 | 2017-11-22 | CureVac AG | Artificial nucleic acid molecules |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| EP2711426B1 (en) * | 2012-09-24 | 2015-04-08 | Lonza Biologics plc | Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences |
| WO2014102103A2 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Heterologous intron within a signal peptide |
| WO2014102100A1 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Heterologous intron within an immunoglobulin domain |
| WO2014102104A1 (en) * | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Artificial introns |
| WO2014102101A1 (en) * | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
| TR201901310T4 (tr) | 2013-03-14 | 2019-02-21 | Translate Bio Inc | Mesajcı RNA'nın saflaştırılması yöntemleri. |
| LT2968586T (lt) | 2013-03-14 | 2018-11-26 | Translate Bio, Inc. | Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
| AU2014375402B2 (en) * | 2013-12-30 | 2020-10-01 | CureVac SE | Artificial nucleic acid molecules |
| CN103901209B (zh) * | 2014-02-18 | 2016-05-25 | 王明丽 | 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒 |
| KR102739894B1 (ko) | 2014-04-25 | 2024-12-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| SG11201609879SA (en) * | 2014-06-18 | 2016-12-29 | Agency Science Tech & Res | Novel promoters for high level expression |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP3585417B1 (en) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Method of making a codon-optimized cftr mrna |
| CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| WO2019060649A1 (en) * | 2017-09-22 | 2019-03-28 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| CA3120647A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3431140A1 (de) * | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
| US5100792A (en) * | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| TW404844B (en) * | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| DE69529495T2 (de) * | 1994-01-21 | 2003-06-12 | Powderject Vaccines, Inc. | Gasbetätigtes element zum austragen von genmaterial |
| DE69536091D1 (de) | 1994-01-27 | 2010-09-09 | Univ Massachusetts Medical | Immunisierung durch Impfung von DNS Transkriptionseinheit |
| EP0836482B1 (en) * | 1995-05-24 | 2002-11-13 | Hawaii Biotechnology Group, Inc. | Subunit vaccine against flavivirus infection |
| US6110707A (en) * | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
| GB9715064D0 (en) * | 1997-07-17 | 1997-09-24 | Ppl Therapeutics Scotland Ltd | Protein expression |
| US20020106635A1 (en) | 1998-05-27 | 2002-08-08 | Bruce Freimark | Cytokine resistant cytomegalovirus promoter mutants and related products and methods |
| EP1123396B1 (en) | 1998-10-19 | 2006-03-08 | Powderject Vaccines, Inc. | Minimal promoters and uses thereof |
| JP2003522159A (ja) | 2000-02-08 | 2003-07-22 | ザ ユニバーシティ オブ ヴァージニア パテント ファウンデーション | 抗Ｃ３ｂ（ｉ）抗体を用いる感染の予防および治療のための方法 |
| GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
| US20030124523A1 (en) * | 2000-06-22 | 2003-07-03 | Asselbergs Fredericus Alphonsus Maria | Organic compounds |
| ATE323166T1 (de) * | 2000-10-13 | 2006-04-15 | Chiron Corp | Fragmente der intron a von citomegalovirus |
| KR20040045391A (ko) | 2000-11-27 | 2004-06-01 | 파우더젝트 백신, 인코포레이티드 | 핵산 어쥬번트 |
| US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| EP1392357A2 (en) | 2001-05-18 | 2004-03-03 | Powderject Vaccines, Inc. | Vaccine composition |
| GB0118367D0 (en) | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
| AU2004280630A1 (en) | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc. | Method |
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
-
2004
- 2004-10-11 ES ES04768811.4T patent/ES2457022T3/es not_active Expired - Lifetime
- 2004-10-11 SG SG200807573-1A patent/SG147430A1/en unknown
- 2004-10-11 BR BRPI0415204-2A patent/BRPI0415204A/pt active Search and Examination
- 2004-10-11 EP EP04768811.4A patent/EP1685251B1/en not_active Expired - Lifetime
- 2004-10-11 KR KR1020117024399A patent/KR101234981B1/ko not_active Expired - Fee Related
- 2004-10-11 US US10/575,087 patent/US8663657B2/en not_active Expired - Fee Related
- 2004-10-11 MX MXPA06003978A patent/MXPA06003978A/es active IP Right Grant
- 2004-10-11 EA EA200600746A patent/EA010056B1/ru not_active IP Right Cessation
- 2004-10-11 PL PL04768811T patent/PL1685251T3/pl unknown
- 2004-10-11 DK DK04768811.4T patent/DK1685251T3/en active
- 2004-10-11 KR KR1020067009012A patent/KR101225395B1/ko not_active Expired - Fee Related
- 2004-10-11 CN CN2004800367871A patent/CN1890375B/zh not_active Expired - Fee Related
- 2004-10-11 NZ NZ546554A patent/NZ546554A/en not_active IP Right Cessation
- 2004-10-11 AU AU2004279991A patent/AU2004279991B2/en not_active Ceased
- 2004-10-11 PT PT47688114T patent/PT1685251E/pt unknown
- 2004-10-11 CA CA002542288A patent/CA2542288A1/en not_active Abandoned
- 2004-10-11 SI SI200432144T patent/SI1685251T1/sl unknown
- 2004-10-11 WO PCT/GB2004/004279 patent/WO2005035771A2/en not_active Ceased
- 2004-10-11 JP JP2006530599A patent/JP4814099B2/ja not_active Expired - Fee Related
-
2006
- 2006-04-06 IL IL174848A patent/IL174848A/en active IP Right Review Request
- 2006-05-09 NO NO20062080A patent/NO20062080L/no unknown
- 2006-05-09 ZA ZA200603685A patent/ZA200603685B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509607A5 (cg-RX-API-DMAC7.html) | ||
| JP6903120B2 (ja) | アルファウイルスワクチン接種のための組成物及び方法 | |
| JP2025084808A (ja) | エプスタイン－バーウイルスワクチン | |
| CN104884082B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| Qi et al. | Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection | |
| CN116390752A (zh) | 自扩增性sars-cov-2rna疫苗 | |
| US6831169B2 (en) | Hepatitis C virus vaccine | |
| WO2020063370A2 (zh) | 免疫组合物及其制备方法与应用 | |
| WO2000011140A1 (en) | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting | |
| CA2447450A1 (en) | Corona-virus-like particles comprising functionally deleted genomes | |
| JP2021509107A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用 | |
| JP2008528020A (ja) | 核酸構築物 | |
| CN101573449A (zh) | 用于治疗慢性乙型肝炎的dna疫苗及其制备方法 | |
| CN120459288A (zh) | 融合蛋白疫苗平台的构建与应用 | |
| US20240335531A1 (en) | Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection | |
| CN114729010B (zh) | 乙型肝炎病毒疫苗 | |
| CN112641937B (zh) | 一种重组腺病毒在制备预防病毒的药物中的用途 | |
| US20220249647A1 (en) | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators | |
| WO2020254876A1 (en) | Virus-like particle delivery of hepatitis b virus (hbv) vaccines | |
| CN118791633A (zh) | 一种预防病毒性心肌炎的细菌样颗粒疫苗及其制备方法和应用 | |
| Zhou et al. | Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine | |
| JP2023546603A (ja) | 外来抗原をコードする遺伝物質を含む、ターゲット組織の大きさまたは体積の縮小用のワクチン組成物またはキット | |
| WO2004072274A1 (en) | Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier | |
| KR102766523B1 (ko) | 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트 | |
| Zhang et al. | A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice |